These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26177273)

  • 21. [Update dyslipidemia].
    Parhofer K
    MMW Fortschr Med; 2016 Apr; 158 Spec No 1():34-40. PubMed ID: 27090675
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Koren MJ; Kereiakes D; Pourfarzib R; Winegar D; Banerjee P; Hamon S; Hanotin C; McKenney JM
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26586732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Strategies to Treat High Cholesterol.
    Blum CB; Stone NJ
    JAMA; 2016 Mar; 315(11):1169. PubMed ID: 26978218
    [No Abstract]   [Full Text] [Related]  

  • 24. Cholesterol limits lose their lustre.
    Ledford H
    Nature; 2013 Feb; 494(7438):410-1. PubMed ID: 23446392
    [No Abstract]   [Full Text] [Related]  

  • 25. New Strategies to Treat High Cholesterol--Reply.
    Shrank WH; Barlow J
    JAMA; 2016 Mar; 315(11):1169-70. PubMed ID: 26978219
    [No Abstract]   [Full Text] [Related]  

  • 26. New therapies to reduce low-density lipoprotein cholesterol.
    Wierzbicki AS; Viljoen A; Hardman TC; Mikhailidis DP
    Curr Opin Cardiol; 2013 Jul; 28(4):452-7. PubMed ID: 23736819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [News in lipid lowering treatment].
    Vrablík M; Češka R
    Vnitr Lek; 2014 Nov; 60(11):949-57. PubMed ID: 25600041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 29. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.
    Stroes ES; Thompson PD; Corsini A; Vladutiu GD; Raal FJ; Ray KK; Roden M; Stein E; Tokgözoğlu L; Nordestgaard BG; Bruckert E; De Backer G; Krauss RM; Laufs U; Santos RD; Hegele RA; Hovingh GK; Leiter LA; Mach F; März W; Newman CB; Wiklund O; Jacobson TA; Catapano AL; Chapman MJ; Ginsberg HN;
    Eur Heart J; 2015 May; 36(17):1012-22. PubMed ID: 25694464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids.
    Shantha GP; Robinson JG
    Clin Pharmacol Ther; 2016 Jan; 99(1):59-71. PubMed ID: 26492546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid Management in Diabetes with a Focus on Emerging Therapies.
    Hoe E; Hegele RA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S183-90. PubMed ID: 26653256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Other therapies for reducing low-density lipoprotein cholesterol: medications in development.
    Stein EA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):99-119. PubMed ID: 19217514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 35. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
    Ferdinand KC; Nasser SA
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Risk of cardiovascular complications cut in half?].
    Einecke D
    MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel therapeutic agents for lowering low density lipoprotein cholesterol.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):31-43. PubMed ID: 22465160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
    Gadi R; Figueredo VM
    J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
    Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
    Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.